CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced the publication of a European study of atrial fibrillation patients treated with CryoCor’s Cardiac Cryoablation System. The purpose of the study was to evaluate the role of atrial flutter in the recurrence of atrial fibrillation and the effectiveness of an ablation strategy focused on isolating the pulmonary veins to treat the atrial fibrillation.

More: continued here

Filed under: Cardiovascular on January 5th, 2008

CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced the publication of a European study of atrial fibrillation patients treated with CryoCor’s Cardiac Cryoablation System. The purpose of the study was to evaluate the role of atrial flutter in the recurrence of atrial fibrillation and the effectiveness of an ablation strategy focused on isolating the pulmonary veins to treat the atrial fibrillation.

More: continued here

Filed under: Cardiovascular on January 5th, 2008